The opportunities in these indications can be assessed by deploying effective new product planning / opportunity assessment methodologies, including evaluating the following for each potential indication: Level of in-class / competitive activity Likelihood of technical and regulatory success (i.e., based on scientific rationale and regulatory precedent) Level and nature of unmet needs for new therapies in the disease area of interest Potential for GLP1-s to address these unmet needs Commercial attractiveness of market Potential speed to market Alignment with individual manufacturer portfolio / strategy / capabilities Conclusion Incretin mimetics have had an immense and growing impact on patient outcomes
In vitro models and systems for evaluating the dynamics of drug delivery to the healthy and diseased brain
NuMedica AdrenaMed GL50 combines adaptogenic herbs, glandular components, and nutrients for stress response, energy balance, and wellness-focused routines
Its predictive value stems from two mechanisms: (1) it directly reflects the long-term depletion of the body's protein reserves
Your doctor will assess risks versus benefits before prescribing
Side effects experienced (type, severity, timing)